Myotonic Dystrophy-1 Complicated by Factor-V (Leiden) Mutation

被引:1
|
作者
Finsterer, Josef [1 ]
Stoellberger, Claudia [2 ]
机构
[1] Krankenanstalt Rudolfstiftung Wien, A-1030 Vienna, Austria
[2] Krankenanstalt Rudolfstiftung Wien, Med Dept Cardiol & Intens Care Med 2, A-1030 Vienna, Austria
关键词
D O I
10.1155/2015/271639
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. Presence of a factor-V Leidenmutation in a patient withmyotonic dystrophy type 1 (DM1) has been reported only once. Here we report the second DM1 patient carrying a factor-V mutation who died from long-term complications of this mutation. Case Report. A 66-year-oldDM1 patient withmulti-organ-disorder syndrome developed a first deep venous thrombosis (DVT) and consecutive pulmonary embolism (PE) at age 50 y. Acetyl-salicylic acidwas given. One year later he experienced a secondDVT; that is why phenprocoumon was started. Despite anticoagulation, he experienced a third DVT bilaterally and a second PE bilaterally at 61 y; that is why a vena cava filter was additionally deployed. Despite therapeutic anticoagulation, he experienced a vena cava filter thrombosis at age 62 y. Genetic workup revealed a heterozygous factor-V mutation in addition to a CTG-repeat expansion of 500. As a consequence of PE he developed chronic obstructive pulmonary disease and experienced recurrent pulmonary infections, which were lastly responsible for decease at age 66 y despite intensive care measures. Conclusion. The heterozygous Leidenmutation may severely affect DM1 patients to such a degree that they die from its complications. If DM1 patients present with unusual manifestations, search for causes other than a CTG-repeat expansion is indicated.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] FACTOR-V LEIDEN MUTATION AND VENOUS THROMBOSIS
    DAVIES, KA
    IRELAND, H
    ATHANASSIOU, P
    LOIZOU, S
    LANE, D
    WALPORT, MJ
    LANCET, 1995, 345 (8942): : 132 - 133
  • [2] FACTOR-V LEIDEN MUTATION AND VENOUS THROMBOSIS
    OZSOYLU, S
    LANCET, 1995, 345 (8942): : 133 - 133
  • [3] UNEXPLAINED THROMBOSIS AND FACTOR-V LEIDEN MUTATION
    ALHENCGELAS, M
    GANDRILLE, S
    AUBRY, ML
    EMMERICH, J
    FIESSINGER, JN
    AIACH, R
    LANCET, 1994, 344 (8921): : 555 - 556
  • [4] BUDD-CHIARI SYNDROME AND FACTOR-V LEIDEN MUTATION
    DENNINGER, MH
    BELDJORD, K
    DURAND, F
    DENIE, C
    VALLA, D
    GUILIN, MC
    LANCET, 1995, 345 (8948): : 525 - 526
  • [5] FACTOR-V LEIDEN AND THROMBOPHILIA
    SIMIONI, P
    SCUDELLER, A
    GIROLAMI, A
    NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (20): : 1382 - 1382
  • [6] COEXISTENCE OF HYPERHOMOCYSTEINEMIA AND FACTOR-V LEIDEN MUTATION - IMPACT ON EXPRESSION OF THROMBOSIS
    MANDEL, H
    BRENNER, B
    BERANT, M
    ROSENBERG, N
    LANIR, N
    JAKOBS, C
    FOWLER, B
    SELIGSOHN, U
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1361 - 1361
  • [7] FACTOR-V LEIDEN - AN UNSELFISH GENE
    HAJJAR, KA
    NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (23): : 1585 - 1587
  • [8] Thrombotic risk of muscular dystrophy: Protein C deficiency, factor V Leiden, and myotonic dystrophy
    Cobos, E
    Phy, M
    Keung, YK
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1999, 5 (03) : 185 - 186
  • [9] WORLD DISTRIBUTION OF FACTOR-V LEIDEN
    REES, DC
    COX, M
    CLEGG, JB
    LANCET, 1995, 346 (8983): : 1133 - 1134
  • [10] EVALUATION OF APC RESISTANCE IN THE PLASMA OF PATIENTS WITH Q506 MUTATION OF FACTOR-V (FACTOR-V LEIDEN) AND TREATED BY ORAL ANTICOAGULANTS
    CADROY, Y
    SIE, P
    ALHENCGELAS, M
    AIACH, M
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (04) : 734 - 735